MedTrace Logo

Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD

NCT05507242 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-08-21

No results posted yet for this study

Summary

A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in patients with COPD.

Conditions

  • COPD
  • COPD Exacerbation
  • COPD Bronchitis
  • Airway Disease
  • Immune System Disorder

Interventions

BIOLOGICAL

Tezepelumab

Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously

OTHER

Placebo

Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University Hospitals, Leicester

    collaborator OTHER

  • Asger Sverrild

    lead OTHER

Principal Investigators

  • Asger Sverrild, MD, PhD · Bispebjerg Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-25
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Denmark
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05507242 on ClinicalTrials.gov